Acute lymphoblastic leukaemia trials in China

In China 169 Also abroad 564

169 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Enrolling by invitation
A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
Where
Tianjin
Age
3 years to 70 years
People
13
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07784309
Phase 1Taking people
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
Where
Beijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou
Age
3 years to 25 years
People
33
Run by
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
See details and how to joinNCT06927466
No phaseTaking people
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
Where
Hainan
Age
18 years to 75 years
People
30
Run by
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
See details and how to joinNCT07763054
No phaseTaking people
Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia
Where
Tianjin
Age
14 years to 60 years
People
43
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07495631
No phaseNot yet taking people in China
Plasma ctDNA Monitoring in Pediatric Acute Leukemia
Where
Tianjin
Age
3 years to 18 years
People
25
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07751588
Phase 2/3Taking people
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Where
Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi’an
Age
1 month to 18 years
People
1,800 worldwide
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06764238
No phaseTaking people
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
Where
Tianjin
Age
14 years and over
People
110
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07493161
Early phase 1Taking people
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Where
Tianjin, Zhengzhou
Age
18 years to 75 years
People
28
Run by
Grit Biotechnology
See details and how to joinNCT07205315
Phase 1Taking people
KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Where
Hangzhou
Age
18 years to 80 years
People
30
Run by
Zhejiang University
See details and how to joinNCT07246707
Early phase 1Not yet taking people in China
Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia
Where
Guangzhou
Age
3 years to 75 years
People
18
Run by
Zhujiang Hospital
See details and how to joinNCT07696481
Phase 2Taking people
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou
Age
18 years and over
People
100
Run by
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07188610
Phase 1Taking people
Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
Where
Beijing
Age
18 years to 70 years
People
60
Run by
Liping Dou
See details and how to joinNCT07677878
Phase 1/2Taking people
Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia
Where
Beijing
Age
18 years to 85 years
People
30
Run by
Liping Dou
See details and how to joinNCT07575971
Early phase 1Taking people
Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Where
Suzhou
Age
18 years and over
People
20
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07074496
Phase 1/2Taking people
Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
Where
Beijing
Age
18 years to 85 years
People
20
Run by
Liping Dou
See details and how to joinNCT07575919
Phase 2Not yet taking people in China
SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
Where
Suzhou
Age
18 years to 65 years
People
180
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07575412
Phase 1Not yet taking people in China
Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
Where
Hefei
Age
3 years to 18 years
People
12
Run by
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07623681
No phaseTaking people
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
Where
Tianjin
Age
14 years to 60 years
People
92
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07454226
Phase 1/2Taking people
Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
Where
Shenzhen
Age
18 years to 75 years
People
10
Run by
Shenzhen University General Hospital
See details and how to joinNCT07584889
Phase 1/2Taking people
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Where
Beijing, Changzhi, Tianjin
Age
16 years to 70 years
People
30
Run by
Chinese PLA General Hospital
See details and how to joinNCT06481735
Phase 1/2Taking people
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
Where
Beijing
Age
3 years to 70 years
People
30
Run by
Peking University People's Hospital
See details and how to joinNCT06874946
Phase 2Taking people
Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
Where
Suzhou
Age
15 years to 65 years
People
101
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07564453
Phase 2Not yet taking people in China
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
Where
Suzhou
Age
15 years to 60 years
People
160
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07562568
Phase 3Taking people
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Where
Bengbu, Chengdu, Chongqing, Guangdong, Shanghai, Suzhou, Tianjin, Wuhan, Zhengzhou
Age
18 years and over
People
350 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06051409 · EU 2024-511496-14-00
Phase 2Taking people
Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
Where
Beijing
Age
12 years to 65 years
People
50
Run by
Chinese PLA General Hospital
See details and how to joinNCT05088226